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Retinal pigment epithelium-specific protein 65 kDa 
(RPE65; OMIM 180069), located on 1p31.3-p31.2, encodes 
a retina-specific, 65 kDa visual cycle protein, retinol isom-
erase, a vital component of the visual cycle [1-3]. Recessive 
mutations in RPE65 can cause severe early onset retinal 
dystrophy, including Leber congenital amaurosis (LCA) 
[4,5]. Patients usually present in infancy or early childhood 
with reduced vision and nyctalopia. The fundus appearance 
tends to be normal in infancy, but small subretinal white dots 
may appear later in childhood that may represent abnormal 
accumulation of retinal esters [6]. Retinal imaging reveals 
a variable thinning of the outer nuclear layer on optical 
coherence tomography (OCT) and a low signal on fundus 
autofluorescence (FAF) imaging, in keeping with reduced 
lipofuscin accumulation in the RPE [7]. Gene replacement 
therapy trials using subretinal administration of recombinant 
adeno-associated viral vectors expressing RPE65 cDNA have 
had promising but unsustained results [8-10].
There was one previous report in 2011 of autosomal 
dominant disease due to a heterozygous mutation in RPE65 
with variable penetrance in two families [11]. The present 
study expands on this report and describes a potential new 
association with adult onset vitelliform macular dystrophy 
(AVMD).
METHODS
The study protocol adhered to the tenets of the Declaration 
of Helsinki and the ARVO guidelines on human subjects in 
research and received approval from the Research Manage-
ment Committee at Moorfields Eye Hospital. Written, 
informed consent was obtained from all participants before 
they were included in the study.
Two families with autosomal dominant retinal disease 
and a fundus appearance compatible with that previously 
reported by Bowne et al. were screened specifically for the 
dominant RPE65 allele [11]. Each patient underwent a full 
clinical examination, including visual acuity and dilated 
fundus examination. When possible, retinal fundus imaging 
was obtained with conventional 35° fundus color photographs 
(Topcon Great Britain Ltd, Berkshire, UK), 30° or 55° fundus 
autofluorescence (FAF) imaging (Spectralis, Heidelberg 
Engineering Ltd, Heidelberg, Germany), and Spectralis 
optical coherence tomography (OCT, Heidelberg Engineering 
Ltd, Heidelberg, Germany). Fundus fluorescein angiographic 
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Purpose: To present a detailed phenotypic and molecular study of two families with autosomal dominant RPE65-related 
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its intron–exon boundaries was performed on all reported patients and segregation confirmed in available relatives. The 
main outcome measures were the results of an ophthalmic examination and investigation and molecular genetic analysis.
Results: Four affected patients from two families presented with nyctalopia and central visual disturbance in adulthood 
progressing to severe visual loss by the fifth to eighth decades. The patients had extensive chorioretinal atrophy with a 
relatively preserved anterior retina. In the second family, one patient had bilateral, vitelliform-like foveal lesions con-
sistent with adult onset vitelliform macular dystrophy and no peripheral retinal changes. These unrelated families were 
both heterozygous for c.1430A>G (p.Asp477Gly). One unaffected family member also tested positive for this mutation 
but had good vision at age 80 years.
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in RPE65. It may manifest with mild disease or be non-penetrant. Awareness of these unusual presentations can facilitate 
targeted molecular investigation.
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images for patient 1.2 were acquired using the Topcon digital 
retinal camera system. Full-field electroretinography (ERG) 
and pattern electroretinography (PERG) were performed 
in two patients using gold foil electrodes to incorporate the 
International Society for Clinical Electrophysiology of Vision 
(ISCEV) standards with electrooculogram (EOG) addition-
ally performed in patient 1.2 [12-14].
Molecular biology: Bidirectional Sanger sequencing of the 
coding region of exon 13 of RPE65 including the intron–
exon boundaries was performed on affected patients, and 
segregation was confirmed in available relatives. Genomic 
DNA was isolated from peripheral blood lymphocytes 
using the Puregene kit (Gentra Puregene Blood Extraction 
Kit, Qiagen, Manchester, UK). DNA was amplified using 
specifically designed primers by polymerase chain reaction 
with BIOTAQ™ DNA polymerase (Bioline, London, UK) at 
an annealing temperature of 65 °C. The resulting fragments 
were sequenced using standard protocols (further details 
available on request). Mutation nomenclature was assigned in 
accordance with GenBank Accession number NM_000329.2 
with nucleotide position 1 corresponding to the A of the ATG 
translation initiation codon.
RESULTS
Five patients from two families were investigated. Clinical 
data are summarized in the Table 1 and Figure 1. Two fami-
lies, both of Irish ancestry, manifested a dominant retinal 
dystrophy. The first family had a choroideremia-like pheno-
type. Patient 1.1 presented with decreased central vision and 
later reported loss of peripheral visual field. At the age of 67 
years, she had visual acuity of 20/60 in the right eye and 20/40 
in the left. By age 74, acuity had deteriorated to 20/200 in the 
right eye and 20/80 in the left. In contrast, her son, patient 
1.2, had more severe disease at an earlier age, developing 
nyctalopia at age 18 years and central visual disturbance at 
age 33 years with deterioration to hand movement vision in 
each eye by age 48 years. Peripheral fields to confrontation 
were still preserved in patches at this age. Fundus examina-
tion in both patients showed extensive chorioretinal atrophy 
with more severe atrophy apparent in the periphery in patient 
1.1 with peripheral increased pigment clumps (Figure 1). The 
OCT for patient 1.2 demonstrated extensive atrophy of the 
outer nuclear and photoreceptor layers, RPE, and choroid 
(Figure 1). In the regions of the preserved retina and RPE, 
outer retinal tubulation was frequently found. Autofluores-
cence imaging showed a generalized loss of autofluorescence 
except sparse, scalloped areas of the preserved retina and 
RPE (Figure 1). Fundus fluorescein angiography in patient 
1.2 demonstrated relatively well-preserved retinal vasculature 
with readily visible choroidal vasculature and no abnormal 
leakage (Figure 2). The ERGs for patient 1.2 at age 33 years 
showed a rod-cone pattern of dysfunction of moderate 
severity with macular involvement (Figure 3). There was 
marked involvement at the level of the RPE as demonstrated 
by an abolished light rise on EOG. No other family members 
were available for examination.
Three members were examined in the second dominant 
family. A mother and son, patients 2.1 and 2.2, presented at 
age 45 and 35 years, respectively, with central visual distur-
bance, which slowly progressed to severe loss of vision. 
Both had widespread chorioretinal degeneration on fundus 
examination with a well-demarcated preserved anterior retina 
and small clumps of increased pigment in the periphery. 
On the OCT of patient 2.2, extensive atrophy of the outer 
nuclear and photoreceptor layers, RPE, and choroid was 
evident with patches of preserved retina and RPE that had 
frequent outer retinal tubulation (Figure 1). OCT through a 
pigment clump in the posterior pole demonstrated a region 
of RPE hypertrophy, not pigment migration (Figure 1). FAF 
imaging highlighted the scalloped regions of the preserved 
retina and RPE with otherwise extensive loss of autofluores-
cence. ERG testing performed in patient 2.1 demonstrated 
severe generalized retinal dysfunction with extinguished rod 
responses and only residual cone related activity (Figure 3). 
Visual fields performed on patient 2.2 demonstrated multiple 
central scotomas at age 36 years on the Goldmann visual 
fields, with some increase in the central scotomas evident 
at age 40 years and extensive central field loss at age 59 
years on Humphrey 24–2 (Figure 4). Patient 2.3, a cousin of 
patient 2.2, developed central visual disturbance at age 40 
years with symptoms of difficulty reading and recognizing 
faces. Visual acuity at age 46 was 20/40 in the right eye and 
20/30 in the left. Vitelliform-like yellow foveal deposits were 
present in both maculae. On OCT, the single dome-shaped 
deposits were demonstrated to involve the RPE and extend to 
the outer retina, displacing the outer plexiform layer (Figure 
1). They showed increased autofluorescence on FAF imaging. 
Patient 2.3 declined further clinical investigation, including 
electrophysiology. His unaffected father was unavailable for 
clinical investigation.
Both families had screened negative for mutations 
in REP1 and PRPH2, and in addition, the c.489C>G 
(p.Ser163Arg) mutation in CIQTNF5 screened negative in 
patient 2.2. Following the report of c.1430 A>G (p.Asp477Gly) 
causing dominantly inherited RPE65-related disease, exon 13 
of the RPE65 gene was screened. In family 1, this identified 
the same previously reported mutation in patients 1.1 and 1.2 
(Figure 5) [11]. In family 2, the same mutation was found in 
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Figure 1. Retinal imaging in dominant RPE65 disease. A, B, C, G, L, O: Color fundus photographs demonstrate extensive chorioretinal 
atrophy in patients 1.1, 1.2, and 2.2, with foveal yellow lesions in patient 2.3. D, H, M, P: Fundus autofluorescence (FAF) imaging demon-
strates extensive loss of autofluorescence in patients 1.2 and 2.2 with scalloped regions of preserved retina and RPE, and increased auto-
fluorescence of foveal deposits in patient 2.3. E, I, N, Q: Optical coherence tomography (OCT) through the fovea demonstrates the loss of 
outer nuclear and photoreceptor layers for patients 1.2 and 2.2, and dome-shaped deposits extending from the RPE to the outer retina for 
patient 2.3. F, J: OCT through the preserved retina and RPE in patients 1.2 and 2.2 with frequent outer retinal tubulation. K: OCT through 
the RPE hypertrophy in patient 2.2. Arrowheads highlight the comparative regions of the preserved retina and RPE. Stars highlight the 
comparative area of RPE hypertrophy.
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all three affected patients and, following segregation in avail-
able family members, was also identified in the asymptomatic 
father of patient 2.3 (with reported normal visual acuity at age 
80 years) and was absent in the unaffected brother of patient 
2.2 (Figure 5).
DISCUSSION
This study presents data from five patients from two families 
with a dominant mutation in RPE65. Four affected patients 
presented in adulthood with central visual disturbance that 
slowly progressed and was associated with extensive chorio-
retinal atrophy. One member of family 2 who carried the 
causative mutation presented with an AVMD phenotype.
Autosomal dominant RPE65 disease has been reported 
previously in two Irish families [11]. Initially, it was identified 
in a large pedigree in whom linkage mapping identified an 
8.8 Mb region on chromosome 1, and then, with candidate 
gene sequencing in parallel with whole exome sequencing, 
the heterozygous p.Asp477Gly mutation was identified. The 
same mutation was also then identified in a second Irish 
family who had been diagnosed with choroideremia but 
who were negative for mutations in REP1 [11]. Intrafamilial 
phenotypic variability was reported with mild disease in 
some affected individuals manifesting as peripheral retinal 
pigment migration only and more severe disease in others 
with extensive chorioretinal atrophy. There were three unaf-
fected at-risk family members and one obligate carrier also 
seemingly unaffected. In the present series, two additional 
families were identified with the same allele, supporting its 
association with retinal dystrophy. The father of patient 2.3 
in this series carries the mutation but is asymptomatic at age 
80 years, confirming that some gene carriers can be non-
penetrant. As he was unavailable for clinical examination, 
sub-clinical retinal changes could have been present.
Both families in this report have Irish ancestry. They 
are not known to be related to each other or to the originally 
reported families, but as the families have the same rare allele 
this raises the likely possibility of a common ancestor. Four 
of the five affected patients presented with severe disease 
that resembles choroideremia with extensive atrophy of 
the outer retina, RPE, and choroid on OCT and scalloped 
patches of the surviving retina. Outer retinal tubulation was 
frequently found in the regions of surviving retina and RPE 
that are thought to indicate invagination of photoreceptors at 
the border of outer retinal atrophy [15]. Choroideremia has 
a similar end stage fundus appearance as dominant RPE65 
disease but typically has an earlier, childhood onset of night 
blindness [16,17]. In addition, the patients in this report 
further differ from choroideremia with prominent early 
Figure 2. Fundus fluorescein angiogram of patient 1.2 at increasing time points. Relative preservation of the retinal vasculature is apparent 
with the easily visible choroidal vasculature. RE, right eye. LE, left eye. Time in minutes.
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central visual disturbance and a relatively preserved anterior 
retina. Choroideremia is an X-linked recessive disorder due to 
hemizygous REP1 mutations and thus predominantly affects 
men with no reported non-penetrance. In female carriers, a 
typical mottled appearance of the RPE most apparent on FAF 
imaging can be detected, but severity varies from asymptom-
atic to severely affected due to random X-inactivation [17]. 
However, it would be unusual for a female carrier to manifest 
as severe disease as observed in patients 1.1 and 2.1.
REP1 is an ubiquitously expressed Rab escort protein 
important in post-translational prenylation of Rab proteins, 
with mutations leading to an accumulation of toxic unprenyl-
ated Rab27A and independent degeneration of the retina and 
the RPE followed by the choroid [18,19]. RPE65, expressed 
Figure 3. Electrophysiology of patients 1.2 and 2.1 with normal (N) for comparison. In both eyes of patient 1.2, there was severely subnormal 
rod-specific electroretinogram (ERG, DA 0.01) delayed and subnormal cone-specific ERGs (LA 30Hz and LA 3.0) and markedly subnormal 
pattern ERG (PERG). Findings were consistent with a rod-cone pattern of dysfunction of moderate severity with bilateral macular involve-
ment. Both eyes of patient 2.1 demonstrated extinguished rod responses and residual cone-related activity with extinguished PERG consistent 
with severe generalized retinal dysfunction and severe macular involvement.
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Figure 4. Visual fields for patient 2.2. A: Goldmann visual fields at ages 36 and 40 years of the left eye (LE) and the right eye (RE) demon-
strate central scotomas increasing over time particularly on the LE. Three different light stimulus sizes and intensities, III4e, I4e, and I3e, 
are indicated with colored isopters. Light stimulus size III is larger than I, and intensity level 4 is greater than 3. B: Humphrey 24–2 visual 
fields at age 59 years demonstrate extensive loss of the central field in both eyes. Mean deviation (MD) indicates the overall average loss of 
field in decibels (dB). Shaded symbols represent probability indicators of the statistical likelihood of the field being normal at that location. 
The darker the symbol, the less likely it is that the field is normal at that tested location.
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in the RPE, is the key visual cycle isomerase, with muta-
tions leading to photoreceptor dysfunction and degenera-
tion followed by RPE degeneration [8]. In dominant RPE65 
disease, the photoreceptor dysfunction has a rod-cone char-
acteristic on ERG, similar to the recessive disease, but in the 
families reported to date, there is much more extensive RPE 
and choroidal degeneration compared to retinal degeneration. 
The cause of disease in the dominant families is unlikely 
to be due to haploinsufficiency of RPE65 as the parents of 
patients with RPE65-related LCA have normal retinal func-
tion [20]. The Asp477Gly mutation is predicted to destabilize 
folding of the tertiary RPE65 structure [11]. One attractive 
hypothesis is that the mutant protein in some, but not all, gene 
carriers has a toxic effect on the RPE, similar to unprenyl-
ated Rab27A, giving rise to the atrophy of the RPE and the 
inner choroid in these patients. In support of this, the EOG in 
patient 1.2 identified an abolished light rise indicating severe 
RPE dysfunction.
The fifth case presented with AVMD. AVMD has previ-
ously been associated with mutations in peripherin 2 (PRPH2; 
OMIM 179605), bestrophin 1 (BEST1, OMIM 607854), and 
interphotoreceptor matrix proteoglycan 1 (IMPG1, OMIM 
602870) but not RPE65 [21-23]. The case in this series was 
phenotypically distinct from BEST1 and was negative for 
mutations on sequencing of PRPH2. He and his unexamined 
father suggest that heterozygotes for this RPE65 allele can 
be mildly affected, but it remains possible that the cause 
of his AVMD is unrelated. Unfortunately, neither one was 
available for electrophysiology or psychophysical testing. In 
dominant retinal disease due to a PRPH2 mutation, retinitis 
pigmentosa and vitelliform macular dystrophy have also been 
shown to cosegregate in the same family [24]. In this context, 
it is possible that the mutant allele has two or more distinct 
toxic effects on the retina that may be modified independently 
by environmental or other genetic factors. In conclusion, 
RPE65-related retinal dystrophy may manifest atypically and 
should be considered in patients presenting with chorioretinal 
atrophy or AVMD in whom targeted molecular screening has 
been negative.
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